Citius Oncology Inc(CTOR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.47 | Insider Own | 71.95% | Shs Outstand | 105.8M | Perf Week | -9.98% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 58.7% | Insider Trans | - | Shs Float | 26.1M | Perf Month | -37.03% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.07 | Inst Own | 15.21% | Short Float | 0.87% | Perf Quarter | -29.94% |
| Income | -0.05B | P/S | 7.19 | EPS this Y | -35.29% | Inst Trans | 0.41% | Short Ratio | 1.83 | Perf Half Y | -42.52% |
| Sales | 0.01B | P/B | 1.44 | EPS next 5Y | - | ROA | -45.2% | Short Interest | 0.23M | Perf YTD | -45% |
| Book/sh | 0.38 | P/C | 3.09 | EPS past 3/5Y | - -309.67% | ROE | -126.58% | 52W High | -69.95% ($1.83) | Perf Year | -67.07% |
| Cash/sh | 0.18 | P/FCF | - | Sales past 3/5Y | - | ROIC | -91.04% | 52W Low | 11.97% ($0.49) | Perf 3Y | -94.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -148.79% | Gross Margin | 28.92% | Volatility(W/M) | 16.7% 13.76% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 6.3 | Sales Y/Y TTM | - | Oper. Margin | -665.63% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | -10.27% | Profit Margin | -648.32% | RSI (14) | 32.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.73 | Sales Q/Q | - | SMA20 | -20.29% ($0.69) | Beta | 3.53 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.25 | Earnings | 2026/8/14 | SMA50 | -33.7% ($0.83) | Rel Volume | 1.51 | Prev Close | $0.59 |
| Employees | - | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | -14.29% -40.25% | SMA200 | -33.74% ($0.83) | Avg Volume(3M) | 0.12M | Price | $0.55 |
| IPO | 2022/12/8 | Option/Short | No/Yes | Trades | 261 | Volume | 188,285 | Change | -7.42% |
🧬 A U.S.-based specialty pharmaceutical company developing and commercializing innovative immuno-oncology treatments for rare hematologic cancers. Through its recently FDA-approved therapy 'LYMPHIR™', the company is delivering a next-generation treatment alternative for patients with refractory cutaneous T-cell lymphoma (CTCL).
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded more than usual. That is 151% of its average volume.
CTOR has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -35.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $719. Peers typically go for $192.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -95.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
SMH VanEck Semiconductor ETF 64.5B 
SOXX iShares Semiconductor ETF 43.2B 
DYNF iShares U.S. Equity Factor Rotation Active ETF 41.6B 
AVEM Avantis Emerging Markets Equity ETF 26.8B 
DRAM Roundhill Memory ETF 18.7B It ranks #60 of 83 in the industry
Based on market cap of $51M.
CPIX#58 Cumberland Pharmaceuticals Inc $65M PER - 
TLPH#59 Talphera Inc $54M PER - CTOR#60 Citius Oncology Inc $51M PER - 
INCR#61 Intercure Ltd $48M PER - 
ZYBT#62 Zhengye Biotechnology Holding Ltd $40M PER - 
FAQ
What kind of company is CTOR?
CTOR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CTOR?
The market cap of CTOR is approximately $51M, ranking 4,830 within its sector.
What is the 52-week high and low for CTOR?
CTOR has recorded a 52-week high of $1.83 and a low of $0.49.
